USA – FDA issues final guidance user fees for combination products
The US Food and Drug Administration (FDA) on Tuesday finalized guidance for sponsors explaining how it assesses user fees for combination products and the different programs available to sponsors for requesting user fee waivers under the Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee Amendments (MDUFA) programs.
The update replaces a final guidance issued in April 2005 to make it more consistent with current user fee programs and to reflect combination product provisions in section 503(g) of the Federal Food and Drug Cosmetic Act (FD&C Act).
More information on the Regulatory Focus Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (19 octobre 2024). USA – FDA issues final guidance user fees for combination products. ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/12jah





